FDA
FDA Articles
GW Pharmaceuticals has announced the positive results of the first pivotal Phase 3 study of its investigational medicine Epidiolex for the treatment of Dravet syndrome.
Published:
Last Updated:
24/7 Wall St. has collected three big FDA decisions coming up in March and added some color, along with the trading range and price target.
Published:
Last Updated:
Amarin made some headway in Wednesday's regular trading session following a settlement with the U.S. Food and Drug Administration.
Published:
Last Updated:
Peregine Pharmaceuticals has announced that it is discontinuing its Phase 3 Sunrise trial of bavituximab in patients with previously treated locally advanced or metastatic non-squamous non-small cell...
Published:
Last Updated:
PTC Therapeutics said that it has received a Refuse to File letter from the FDA regarding its New Drug Application for Translarna (ataluren).
Published:
Last Updated:
Trevena charged after the FDA granted a Breakthrough Therapy designation to its lead product candidate for the management of acute pain.
Published:
Last Updated:
Chimerix had a bad start to the week as it tumbled in early trading on Monday, following some late stage clinical trial results.
Published:
Last Updated:
Over the past week, Zafgen and a few other biotech companies made impressive runs. These moves were the result of positive trial results and an FDA meeting.
Published:
Last Updated:
Ocular Therapeutix led the bulls in early trading indications on Thursday, following a positive meeting with the FDA.
Published:
Last Updated:
Here are six biotech and pharma stocks that analysts are telling their firm's clients to buy now for solid upside opportunities ahead.
Published:
Last Updated:
CTI BioPharma has practically become a penny stock overnight following an update from its Investigational New Drug (IND) application for pacritinib.
Published:
Last Updated:
Adaptimmune Therapeutics has announced that the FDA granted a Breakthrough Therapy designation for the company's affinity enhanced T-cell therapy.
Published:
Last Updated:
Exelixis shares were rising early Monday following the release of positive results from its late-stage trial of cabozantinib.
Published:
Last Updated:
24/7 Wall St. has collected three big FDA decisions coming up in February and added some color, along with the trading range and price target.
Published:
Last Updated:
Relypsa rose early in Monday’s session as the result of positive results from its Phase 1 in vivo studies evaluating the interactions between Veltassa (patiromer) and other drugs.
Published:
Last Updated: